AgeneBio announced two grant awards to advance their approaches to slowing progression of mild cognitive impairment (MCI) due to Alzheimer's Disease (AD).
MCI due to AD is an intermediate stage between normal cognition and Alzheimer's dementia in which memory and cognitive abilities are markedly worse than expected for a person's age.